Moderna (NASDAQ:MRNA) shares rose sharply on Thursday, advancing roughly 10% as market attention focused on a hantavirus outbreak associated with the expedition cruise ship MV Hondius. The move in the stock came the same day health officials and scientific outlets reported developments tied both to the outbreak and to Moderna's vaccine research.
Outbreak details and immediate response
The World Health Organization reported that eight hantavirus cases have been identified among people connected to the MV Hondius. Of those eight cases, three are confirmed infections and five are suspected. Health authorities across several countries are engaged in tracing and containment work related to the incident.
The vessel is en route to Spain's Canary Islands with passengers still on board. Oceanwide Expeditions, the ship operator, said two passengers in serious condition were evacuated and taken to the Netherlands for treatment; a third evacuee who is not currently showing symptoms is also receiving care there. The evacuees comprise a British national, a 65-year-old German and a 41-year-old Dutch crew member.
Spanish Health Minister Monica Garcia said the MV Hondius, which has nearly 150 people on board, is expected to dock in Tenerife within three days. She added that those still on the ship were not presenting symptoms.
Fatalities and origin questions
Three deaths have been reported in connection with the situation, and officials have confirmed that one of the deceased had the virus. The other two deaths are still subject to investigation. The origin of the outbreak remains unknown and authorities have said it is unclear whether any people outside the ship's passenger and crew list have been infected.
Hantaviruses are typically transmitted by rodents. An international scientific team with researchers from the University of Bath, the United States and South Africa is working on a hantavirus vaccine, according to statements about the response effort.
Moderna reaction and vaccine data
Moderna's stock movement coincided with the company's announcement that positive Phase 3 results for its seasonal influenza vaccine candidate, mRNA-1010, have been published in the New England Journal of Medicine. The peer-reviewed article presents safety and efficacy data from the Phase 3 study that evaluated the vaccine in adults aged 50 years and older against a licensed standard-dose seasonal influenza vaccine.
Market participants reacted to both the outbreak developments and the vaccine publication on the same day, lifting Moderna shares as investors processed the dual headlines.
What is known and what remains uncertain
Relevant facts remain limited in certain areas: the precise source of the outbreak has not been identified, investigations into two of the reported deaths are ongoing, and public health authorities have not confirmed infections beyond those linked to the ship. Health officials continue contact tracing and containment efforts while the vessel approaches port.
Given the current information, officials are concentrating on care for the evacuated patients, tracing potential exposures and investigating the fatalities. Additional updates from health authorities and scientific teams were anticipated as investigations proceed.